• For readers wondering whether Indivior Pharmaceuticals at around US$28.97 is still a good entry point or more of a hold after such a big run, this article focuses squarely on what the current valuation is indicating.
• The stock has pulled back, with a 1.4% decline over the last 7 days, an 11.5% decline over 30 days, and an 18.9% decline year to date. This follows a very strong 204.0% return over 1 year and 216.6% over 5 years.
• Recent attention around Indivior Pharmaceuticals has centered on how the market is reassessing companies in the pharmaceuticals and biotech space, and how that reassessment shows up in prices after large multi year moves. This context helps explain why a stock with a 72.9% 3 year return and a 204.0% 1 year return can still experience shorter term pullbacks.
• Indivior Pharmaceuticals currently scores 5 out of 6 on Simply Wall St's valuation checks. The next sections will walk through the different valuation methods behind that score and will also outline an even more detailed way to think about value at the end of the article.

Indivior Pharmaceuticals delivered 204.0% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Indivior Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a business may generate in the future and discounts those back into today’s dollars to arrive at an estimate of intrinsic value per share.

For Indivior Pharmaceuticals, the DCF model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $80.2 million, so the model relies heavily on projections. Analyst estimates and Simply Wall St extrapolations point to free cash flow reaching $536.5 million in 2030, with annual figures between 2026 and 2035 ranging from $379.1 million to $656.3 million in projected free cash flow.

Discounting these projected cash flows back to today gives an estimated intrinsic value of about $109.43 per share. Compared with a current share price around $28.97, the model suggests Indivior Pharmaceuticals trades at a 73.5% discount to this DCF estimate. This represents a wide gap for readers who rely on cash flow based valuation.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Indivior Pharmaceuticals is undervalued by 73.5%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Indivior Pharmaceuticals.

Approach 2: Indivior Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to relate what you pay for a share to the earnings that each share generates. It helps you see how many years of current earnings the market is pricing in, which is often how investors quickly compare opportunities.

What counts as a “normal” or “fair” P/E depends on what the market expects for growth and how risky those earnings appear. Higher expected growth or perceived resilience can justify a higher P/E, while slower growth or higher risk usually lines up with a lower P/E.

Indivior Pharmaceuticals currently trades on a P/E of 16.8x. That sits close to the Pharmaceuticals industry average of 16.7x and below the peer group average of 34.9x. Simply Wall St’s Fair Ratio for the stock is 21.5x, which is its proprietary view of what the P/E could be given factors like earnings growth, profit margins, industry, market cap and specific risks. This Fair Ratio can be more tailored than a simple comparison with peers or the broad industry because it adjusts for those company level characteristics. Comparing the current P/E of 16.8x with the Fair Ratio of 21.5x points to the shares trading below that Fair Ratio input.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Indivior Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about Indivior Pharmaceuticals to the numbers by linking your view of its future revenue, earnings and margins to a financial forecast. This converts that into a Fair Value you can compare with the current price to help frame buy or sell decisions. Your view is then updated automatically when new information arrives. For example, one investor on the Community page might build a more optimistic Indivior narrative around a Fair Value of US$50.00, while another anchors a more cautious view closer to US$37.86, even though both are using the same underlying business data.

Do you think there's more to the story for Indivior Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.